Community-Acquired Pneumonia: Clinical Trials

29 trials for Community-Acquired Pneumonia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 3 not yet recruiting, 3 terminated, 3 withdrawn. 29 Phase 2, 5 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 229Completed 14, Not yet recruiting 3, Terminated 3, Withdrawn 3, Active not recruiting 2, Recruiting 2, Unknown 2
Phase 35Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1
Phase 12Completed 1, Not yet recruiting 1

Follow Community-Acquired Pneumonia: new trials by email Literature Review of Community-Acquired Pneumonia trials Research Report on Community-Acquired Pneumonia

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
Inhaled levofloxacin, Standard-of-care / Usual care - Community-acquired Pneumonia, CAP
Phase 2 / Phase 3Active not recruitingCopenhagen Respiratory Research4602026-10-082026-11-05
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
NRICM102, Placebo, Intravenous Antibiotic - Mild to Moderate, Community-Acquired Pneumonia (CAP)
Phase 2Not yet recruitingNational Research Institute of Chinese Medicine, Ministry of Health and Welfare1502026-06-012026-05-13
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Phase 2WithdrawnImmunityBio, Inc.2026-04-152026-05-08
Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia
Methylprednisolone - Acute Respiratory Failure, Community-Acquired Pneumonia
Phase 1 / Phase 2Not yet recruitingQingyuan Zhan5002026-02-012026-01-22
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl) - Severe Community-acquired Pneumonia (sCAP)
Phase 2 / Phase 3Not yet recruitingQingyuan Zhan15002025-09-082025-09-03
Local Antibiotic Delivery for Community Acquired Pneumonia
Levofloxacin, Placebo - Community Acquired Pneumonia (CAP)
Phase 2 / Phase 3Active not recruitingCopenhagen Respiratory Research362025-03-042026-11-06
Efficacy and Safety of SR1375 in Adult Patients With CAP
SR1375 capsule 3mg+regular treatments, SR1375 capsule 1mg+regular treatments, SR1375 capsule 0.3mg+regular treatments - Community-acquired Pneumonia
Phase 2RecruitingShanghai SIMR Biotechnology Co., Ltd.2402024-09-102025-07-09
CX-4945 in Viral Community Acquired Pneumonia
CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
Phase 2TerminatedSenhwa Biosciences, Inc.452024-03-202026-01-08
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
AON-D21, Placebo - Community-acquired Pneumonia
Phase 2CompletedAptarion Biotech AG1502024-02-022026-03-18
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
Augmentin ES - Infections, Bacterial
Phase 2WithdrawnGlaxoSmithKline2023-10-142025-03-28
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
Anakinra Prefilled Syringe, Placebo - Community-acquired Pneumonia, Hospital-acquired Pneumonia
Phase 2CompletedHellenic Institute for the Study of Sepsis602023-03-062024-07-31
Corticosteroids in Community Acquired Pneumonia
Prednisone, Placebo - Community-acquired Pneumonia, Cognition Disorder
Phase 2WithdrawnVanderbilt University Medical Center2020-12-012023-02-08
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Allocetra-OTS, Placebo - Sepsis, Community-acquired Pneumonia
Phase 2CompletedEnlivex Therapeutics Ltd.1482020-11-302025-08-19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
Trimodulin, Placebo (human albumin 1%) - Covid19
Phase 2CompletedBiotest1662020-10-062023-01-10
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Recombinant Human Plasma Gelsolin, Normal Saline Placebo - Community-acquired Pneumonia
Phase 1 / Phase 2CompletedBioAegis Therapeutics Inc.332018-08-282020-01-27
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
Amoxicillin - Community-acquired Pneumonia
Phase 2 / Phase 3RecruitingSt. Justine's Hospital13702017-06-112026-11-18
Ticagrelor in Severe Community Acquired Pneumonia
Ticagrelor, Placebo - Community Acquired Pneumonia, Severe
Phase 2TerminatedGordon Bernard252014-08-012017-12-11
Short Duration Treatment of Non-severe Community Acquired Pneumonia
Chest X-ray, blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry, Augmentin - Community Acquired Pneumonia
Phase 2UnknownVersailles Hospital3102013-11-012017-08-14
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate - Infections, Community Acquired Pneumonia
Phase 2 / Phase 3CompletedForest Laboratories1612012-09-012015-01-13
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
BT086, 1% Human Albumin infusion - Community Acquired Pneumonia
Phase 2CompletedBiotest1602011-08-012015-07-29

Showing 20 of 29. Sign in to see all of them.

Narrower conditions

Pneumonia (6)  ·  Sepsis (4)  ·  COVID-19 (2)  ·  Respiratory Distress Syndrome (2)  ·  Asthma (1)  ·  Bacterial Infections (1)  ·  Cholecystitis, Acute (1)  ·  Cognition Disorders (1)  ·  Healthcare-Associated Pneumonia (1)  ·  Infections (1)  ·  Influenza, Human (1)  ·  Intraabdominal Infections (1)  ·  Lymphoma, Follicular (1)  ·  Lymphopenia (1)

Broader conditions

Community-Acquired Infections (29)  ·  Respiratory Tract Diseases (29)  ·  Respiratory Tract Infections (29)  ·  Infections (28)  ·  Pneumonia (23)  ·  Lung Diseases (11)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Inflammation (4)  ·  Systemic Inflammatory Response Syndrome (4)  ·  Immune System Diseases (3)  ·  Bacterial Infections and Mycoses (2)  ·  Coronaviridae Infections (2)  ·  Coronavirus Infections (2)  ·  Disease Attributes (2)

Interventions

Amoxicillin-Potassium Clavulanate Combination (3)  ·  Levofloxacin (3)  ·  Cell Count (2)  ·  ALT-803 (1)  ·  Amoxicillin (1)  ·  Blood Specimen Collection (1)  ·  C-Reactive Protein (1)  ·  Ceftaroline (1)  ·  Ceftriaxone (1)  ·  Duration of Therapy (1)  ·  EDP 420 (1)  ·  Ertapenem (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Methylprednisolone (1)  ·  Methylprednisolone Hemisuccinate (1)

Sponsors

Biotest (2)  ·  Copenhagen Respiratory Research (2)  ·  Qingyuan Zhan (2)  ·  TaiGen Biotechnology Co., Ltd. (2)  ·  Aptarion Biotech AG (1)  ·  BioAegis Therapeutics Inc. (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Enanta Pharmaceuticals, Inc (1)  ·  Enlivex Therapeutics Ltd. (1)  ·  Forest Laboratories (1)  ·  GlaxoSmithKline (1)  ·  Gordon Bernard (1)  ·  Hellenic Institute for the Study of Sepsis (1)  ·  IASO Pharma Inc. (1)  ·  ICOS Corporation (1)

Countries

United States (8)  ·  Spain (5)  ·  France (4)  ·  Belgium (3)  ·  China (3)  ·  Germany (3)  ·  Taiwan (3)  ·  Brazil (2)  ·  Canada (2)  ·  Denmark (2)  ·  Georgia (2)  ·  Greece (2)  ·  Poland (2)  ·  Russia (2)  ·  South Africa (2)

Top investigators

AJ Bester, Doctor (1)  ·  Antoni Torres, MD (1)  ·  CT de Villiers, Doctor (1)  ·  DJ Jansen van Rensburg, Doctor (1)  ·  E van Nieuwenhuizen, Doctor (1)  ·  Evangelos Giamarellos-Bourboulis, MD, PhD (1)  ·  G Nieuwoudt, Doctor (1)

Results publications

PMID 26748734, PMID 27093162, PMID 29632995, PMID 32690640, PMID 33351126, PMID 33773631, PMID 38734138, PMID 39138518, PMID 41552367